Tagrisso and Neoplasm malignant - a phase IV clinical study of FDA data

Summary:

Neoplasm malignant is reported as a side effect among people who take Tagrisso (osimertinib mesylate), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Iressa, and have Lung cancer - non-small cell.

The phase IV clinical study analyzes which people have Neoplasm malignant when taking Tagrisso. It is created by eHealthMe based on reports of 19,861 people who have side effects when taking Tagrisso from the FDA, and is updated regularly.

What is Tagrisso?

Tagrisso has active ingredients of osimertinib mesylate. eHealthMe is studying from 19,890 Tagrisso users. Check the latest studies of Tagrisso.

What is Neoplasm malignant?

Neoplasm malignant (cancer tumour) is found to be associated with 1,536 drugs and 1,261 conditions by eHealthMe. Check the latest studies of Neoplasm malignant.

On Jul, 15, 2026

19,861 people reported to have side effects when taking Tagrisso.
Among them, 77 people (0.39%) have Neoplasm malignant.

Could Tagrisso cause Neoplasm malignant?

Among these 77 people:

How long have people been on Tagrisso when they have Neoplasm malignant? *

What is the gender of people who have Neoplasm malignant when taking Tagrisso? *

female: 62.12 %
male: 37.88 %

What is the age of people who have Neoplasm malignant when taking Tagrisso? *

What are other drugs people take besides Tagrisso? *

What are other side effects people have besides Neoplasm malignant? *

Drug Ineffective: 7 people, 9.09%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 7 people, 9.09%
Death: 7 people, 9.09%
Fatigue (feeling of tiredness): 6 people, 7.79%
Hypophagia (reduced food intake): 5 people, 6.49%
Dry Skin: 5 people, 6.49%
Metastases To Central Nervous System (cancer spreads to central nervous system): 4 people, 5.19%
Malignant Neoplasm Progression (cancer tumour came back): 4 people, 5.19%
Swallowing Difficulty: 4 people, 5.19%
Stress And Anxiety: 4 people, 5.19%

What are the existing conditions these people have? *

Lung Cancer - Non-Small Cell (lung cancer): 14 people, 18.18%
Lung Neoplasm Malignant (cancer tumour of lung): 12 people, 15.58%
Non-Small Cell Lung Cancer Metastatic (type of epithelial lung cancer spreads to other parts): 6 people, 7.79%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 3 people, 3.90%
Bronchial Carcinoma (lung cancer): 2 people, 2.60%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 2 people, 2.60%
Depression: 1 person, 1.30%
Diabetes: 1 person, 1.30%
Gastritis - Chronic (long lasting inflammation of stomach): 1 person, 1.30%
Immunodeficiency: 1 person, 1.30%

* Approximation only. Some reports may have incomplete information.

Do you take Tagrisso and have Neoplasm malignant?

- Check whether Neoplasm malignant is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tagrisso:

Tagrisso (19,890 reports)

Browse all side effects of Tagrisso:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Neoplasm malignant:

Neoplasm malignant (1,536 drugs)

Browse all the conditions that are associated with Neoplasm malignant:

Neoplasm malignant (1,261 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on osimertinib mesylate (the active ingredients of Tagrisso) and Tagrisso (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.